Eun Yang
Stock Analyst at Jefferies
(0.80)
# 3,001
Out of 4,412 analysts
36
Total ratings
35.71%
Success rate
-24.47%
Average return
Main Sectors:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTE Aerovate Therapeutics | Assumes: Buy | $21 → $65 | $21.57 | +201.34% | 2 | Mar 25, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $9.17 | +194.44% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $1.65 | -9.09% | 2 | Feb 7, 2024 | |
| RPHM Reneo Pharmaceuticals | Downgrades: Hold | $17 → $1.8 | $1.65 | +9.09% | 2 | Dec 15, 2023 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $24.33 | +35.64% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $10.47 | +167.43% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $16.78 | +60.91% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.13 | +228.64% | 1 | Feb 10, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Hold | $14 → $1.5 | $2.30 | -34.78% | 1 | Feb 1, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $2.31 | - | 2 | Jan 9, 2023 | |
| LUMO Lumos Pharma | Downgrades: Hold | $17 → $7 | $2.76 | +153.62% | 3 | Dec 8, 2022 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $4.30 | +481.40% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $21 → $3 | $3.81 | -21.26% | 1 | Sep 22, 2022 | |
| BPMC Blueprint Medicines | Maintains: Buy | $78 → $84 | $90.73 | -7.42% | 3 | Aug 22, 2022 | |
| UTHR United Therapeutics | Maintains: Buy | $223 → $245 | $235.95 | +3.84% | 3 | May 24, 2022 | |
| PYXS Pyxis Oncology | Initiates: Buy | n/a | $4.30 | - | 1 | Nov 2, 2021 | |
| VERV Verve Therapeutics | Initiates: Buy | n/a | $6.22 | - | 1 | Jul 12, 2021 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | n/a | $8.93 | - | 1 | Jun 22, 2021 | |
| AMGN Amgen | Maintains: Buy | n/a | $269.38 | - | 2 | Jul 27, 2018 | |
| RDUS Radius Health | Maintains: Hold | n/a | $18.14 | - | 1 | Nov 3, 2017 | |
| ALRN Aileron Therapeutics | Initiates: Buy | n/a | $5.00 | - | 1 | Jul 24, 2017 | |
| BIIB Biogen | Assumes: Hold | n/a | $202.46 | - | 1 | Jul 11, 2017 | |
| GILD Gilead Sciences | Assumes: Hold | n/a | $65.27 | - | 1 | Jul 11, 2017 |
Aerovate Therapeutics
Mar 25, 2024
Assumes: Buy
Price Target: $21 → $65
Current: $21.57
Upside: +201.34%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $9.17
Upside: +194.44%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $1.65
Upside: -9.09%
Reneo Pharmaceuticals
Dec 15, 2023
Downgrades: Hold
Price Target: $17 → $1.8
Current: $1.65
Upside: +9.09%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $24.33
Upside: +35.64%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $10.47
Upside: +167.43%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $16.78
Upside: +60.91%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.13
Upside: +228.64%
Taysha Gene Therapies
Feb 1, 2023
Downgrades: Hold
Price Target: $14 → $1.5
Current: $2.30
Upside: -34.78%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.31
Upside: -
Lumos Pharma
Dec 8, 2022
Downgrades: Hold
Price Target: $17 → $7
Current: $2.76
Upside: +153.62%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $4.30
Upside: +481.40%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $3
Current: $3.81
Upside: -21.26%
Blueprint Medicines
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $90.73
Upside: -7.42%
United Therapeutics
May 24, 2022
Maintains: Buy
Price Target: $223 → $245
Current: $235.95
Upside: +3.84%
Pyxis Oncology
Nov 2, 2021
Initiates: Buy
Price Target: n/a
Current: $4.30
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $6.22
Upside: -
Centessa Pharmaceuticals
Jun 22, 2021
Initiates: Buy
Price Target: n/a
Current: $8.93
Upside: -
Amgen
Jul 27, 2018
Maintains: Buy
Price Target: n/a
Current: $269.38
Upside: -
Radius Health
Nov 3, 2017
Maintains: Hold
Price Target: n/a
Current: $18.14
Upside: -
Aileron Therapeutics
Jul 24, 2017
Initiates: Buy
Price Target: n/a
Current: $5.00
Upside: -
Biogen
Jul 11, 2017
Assumes: Hold
Price Target: n/a
Current: $202.46
Upside: -
Gilead Sciences
Jul 11, 2017
Assumes: Hold
Price Target: n/a
Current: $65.27
Upside: -